Ariad says AP26113 continues to show promise in advanced NSCLC

|By:, SA News Editor

At the European Cancer Congress, Ariad Pharmaceuticals (ARIA) gives an update on the Phase 1/2 trial of AP26113.

According to the company, the tyrosine kinase inhibitor demonstrated "robust anti-tumor activity" in patients with TKI-naïve and crizotinib-resistant ALK+  non-small cell lung cancer.

Additionally, it appears the drug is active in patients with brain metastases. (PR)